## **Gladiator Stocks**



New recommenda	ations					Time Frame: 6 Months
Date	Scrip	I-Direct Code	Buying Range	Target	Stoploss	Upside (%)
16-Sep-20	Oberoi Realty	OBEREA	400.00-418.00	485.00	367.00	17
Open recommend	ations					Time Frame: 6 Months
Date	Scrip	Avg Rec Price	Target	Stoploss	CMP	Return till date (%)
16-Sep-20	Automotive Axles	750.00	870.00	673.00	764.0 <mark>0</mark>	2%
3-Sep-20	Ajanta Pharma	/1,510.00	1,760.00	/ 1,390.00	1, <mark>536.0</mark> 0	2%
3-Sep-20	Sun Pharma	518.00	605.00	467.00	508.00	-2%
21-Aug-20	Cummins India	458.00	540.00	410.00	478.00	4%
18-Aug-20	Britannia Industries	3,812.00	4,510.00	3,560.00	3,800.00	0%
11-Aug-20	Berger Paints	547.00	635.00	497.00	580.00	6%
1-Jun-20	Pidilite Industries	1,470.00	1,670.00	1,320.00	1,499.00	2%

	Open Recommendations  Momentum Picks				
	Scrip	Action			
	Himatsingka Siede	Buy			
20	CYIENT	Buy			
	Durati	on: 14 Days			
3	Click here to know	w more			
<u>_</u>					

**September 16, 2020** 

#### **Research Analysts**

**Dharmesh Shah** 

dharmesh.shah@icicisecurities.com

All the recommendations are in Cash segment

Pabitro Mukherjee

pabitro.mukherjee@icicisecurities.com

Nitin Kunte, CMT

nitin.kunte@icicisecurities.com

Vinayak Parmar


vinayak.parmar@icicisecurities.com

Ninad Tamhanekar, CMT

ninad.tamhanekar@icicisecurities.com

# Oberoi Realty (OBEREA): Breakout from base formation at key support threshold offers fresh entry opportunity...





### Fundamental View: Oberoi Realty



#### Residential pain imminent; Consolidation in industry likely

The sharp volume decline amid Covid-19 was an exacerbation of already struggling residential real estate due to weak macroeconomic conditions. The company has maintained its target to launch Thane project by Diwali, subject the normalisation of Covid-19. The company, however, termed the pandemic led dislocation to be the precursor of the industry consolidation with weak players likely to shut shop. While we concur with company's assessment, we also believe that pain could be elongated considering the big ticket size of real estate as well as relatively steeper impact on key cities including Mumbai. Given the pandemic impact, we lower ORL's sales volume estimates to 0.7 msf in FY21 (vs. 1.7 msf earlier), while we bake in 1.7 msf volumes in FY22E, with Thane/ Goregaon Phase III, kicking in. We expect the launch timelines of residential to be a function of pandemic status, rather than company's plan.

#### Commercial vertical stable; mall, hospitality outlook dim

The commercial segment is the only stable vertical in the current condition. Among operational assets, the company expects Commerz I to revert back to 70% occupancy by Q2 end/Q3 beginning post fitout by a lessee. ORL has signed an agreement with Morgan Stanley to lease 1.1 million square feet at Commerz III from 2023 on a long term lease agreement of 9.5 years, which is a key positive. The Borivali mall is expected to be delayed by six months (vs. earlier target of Q4FY21E opening), while Worli hospitality (to be restructured) and mall project, has been put on hold. The company is not expecting much cash burn in Westin, given no project level leverage. Negotiation of rental waiver continues for Oberoi Mall, post which the company can recognise some revenues (recognised zero revenues in Q1).

#### Fund raising and expansion plans

The company's board has also passed enabling resolutions for issue of non-convertible debentures up to ₹ 1,500 crore by way of private placement as well as issue of equity shares for up to ₹ 2,000 crore by way of QIP. The company termed it as usual enabling resolution, which could be utilised to capture opportunities. It also added that it continues to look for expansion in the NCR and Bengaluru market if it gets any attractive opportunities

• Near term challenges in the residential demand, hospitality segment and mall are visible but ORL is well positioned to tide over the same with comfortable debt levels and above mentioned fund raise. Nonetheless, we expect recovery to be a slow grind with demand recovery atleast taking a year, and build in slower volumes traction, going ahead

Particulars	
Particular	₹crore
Market Capitalization	15,136.7
Total Debt	1,143.9
Cash	108.3
EV	16,172.3
52 w eek H/L (₹	642 / 438
Equity capital	363.6
Face value (₹	10.0

Financials			
₹crore	FY20	FY21E	FY22E
Net Sales	2,238	1,269	2,186
EBITDA	1,048	510	989
Net Profit	689	269	617
EPS (₹	19.0	7.4	17.0

Key Metrics			
	FY20	FY21E	FY22E
P/E (x)	22.0	56.2	24.5
EV/EBITDA	13.1	27.1	13.9
P/B (x)	1.8	1.7	1.6
RoNW (%)	7.9	3.0	6.6
RoCE (%)	10.8	4.6	9.0



### Follow up summary of Gladiator Stocks



Summary Performance - Recommendations till date					
Total Recommendations	566	Open	7		
Closed Recommendations	559	Yield on Positive recommendations	17.0%		
Positive Recommendations	413	Yield on Negative recommendations	-8.0%		
Closed at cost	16				
Strike Rate	76%				

### Momentum Picks open recommendations




Date	Scrip Name	Strategy	Recommendations Price	Target	Stoploss	Time Frame
16-Sep-20	Himatsingka Seide	Buy	85-87	96.00	78.00	14 days
15-Sep-20	CYIENT	Buy	400-411	455.00	384.00	14 days

All the recomedations are in Cash segment

**Back to Top** 

### Price history of past three years





### **Product Guidelines.....**



- · It is recommended to enter in a staggered manner within the prescribed range provided in the report
- Once the recommendation is executed, it is advisable to keep strict stop loss as provided in the report on closing basis
- The recommendations are valid for six months and in case we intend to carry forward the position, it will be communicated through separate mail

#### Trading portfolio allocation

- It is recommended to spread out the trading corpus in a proportionate manner between the various technical research products
- Please avoid allocating the entire trading corpus to a single stock or a single product segment
- Within each product segment it is advisable to allocate equal amount to each recommendation
- For example: The 'Momentum Picks' product carries 2 intraday recommendations. It is advisable to allocate equal amount to each recommendation

### Recommended product wise trading portfolio allocation



Product		ations Max allocation In 1 Stock	Number of Calls	Return Objective	Duration
Momentum Picks Intraday	s- 10%	30-50%	2 Stocks	1-2%	Intraday
Momentum Picks Positional	s- 25%	8-10%	8-10 Per Month	5-8%	14 Days
Gladiator Stocks	35%	10-13%	Opportunity Based	15-20%	6 Months
Yearly Technical	25%	12-15%	7-9 Per Year	20-30%	1 Year
Cash	5%				
	100%				

\_





Pankaj Pandey

Head – Research

ICICI Direct Research Desk,

ICICI Securities Limited,

1st Floor, Akruti Trade Centre,

Road No 7, MIDC,

Andheri (East)

Mumbai – 400 093

research@icicidirect.com

pankaj.pandey@icicisecurities.com

### Disclaimer



We /l, Dharmesh Shah, Nitin Kunte, Ninad Tamhanekar, Pabitro Mukherjee, Vinayak Parmar Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance investing in the securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance investing in the securities and the risks associated before investing in the securities may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.